Hematological malignancies
Conditions
Interventions
Case series:None
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Hospitalized patients diagnosed with hematologic malignancies (all types of hematolymphoid tumours and all types of monoclonal gammopathies of clinical significance, including multiple myeloma according to the 2022 WHO classification) and with previous coronavirus infection (positive test for COVID-19 nucleic acids or antibodies). Their diagnostic information will be obtained from the hospital's reliable electronic medical record system. This population include patients with or without previous exposure to antiviral agents.
Exclusion criteria
Exclusion criteria: 1. Patients who died definitely unrelated to coronavirus infection during hospitalization(such as patients with sudden death caused by cerebral hemorrhage due to hyperleukocytosis); 2. Patients who have been treated with serum from convalescents.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The remission rate of coronavirus infection;The exacerbation rate of coronavirus infection;The clearance rate of pathogens;Mechanical ventilation rate;ICU transfer rate;Death rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Effect of different types of hematological malignancies on primary outcomes;Effect of the types and exposure time of anti-viral drugs on primary outcomes;Effect of recent chemotherapy on primary outcomes;Effect of types of chemotherapy on primary outcomes;Effect of granulocyte and lyphocyte deficiency on primary outcomes;Effect of vaccination status on primary outcomes; | — |
Countries
China
Contacts
Public ContactWu Yu
West China Hospital, Sichuan University
Outcome results
None listed